Moderna's cancer vaccine data just doubled the stock
A Phase 3 melanoma win with Merck triggered a historic short squeeze.
What's happening
Moderna and Merck reported the first positive Phase 3 result for an mRNA neoantigen cancer therapy in melanoma, and the stock responded immediately — Decrypt and Ars Technica both confirm the trial success, while Yahoo Finance reports the stock surged as much as 160%, roughly doubling, with at least one analyst upgrade on the back of the data.
The numbers
Only 9 recent mentions and breadth of 2, but the price move dwarfs the chatter volume: a 160% surge described as burning short sellers out of a reported $5 billion in losses.
Our read
Real, and not close. Low chatter breadth is irrelevant here — the signal is in the price, and a mega-cap biotech doubling on a single trial readout with named short-seller losses is about as confirmed as this gets. Watch for Merck's own confirmation language and whether the melanoma result extends to other cancer types, since that's what decides if this holds or fades like past mRNA-pipeline spikes.
Sources we checked
- Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means — decrypt.co
- mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say — arstechnica.com
- Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss — finance.yahoo.com
- This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results — finance.yahoo.com
- Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma — twitter.com
- Today's blog post:I got my fall COVID shot and flu shot. All went well, except I didn't get the Moderna mRNA flu vaccine, due to availability issues. The Sanofi — @weekend_editor@mathstodon.xyz
- RE: https://bots.robots.rodeo/@scream/117385158704235339Obrigado pela sociedade moderna, que me entrega exatamente oq eu preciso nesse momento especÃfico: — @dragoniff2@kolektiva.social
See today's live board
This story is frozen as published on October 6, 2026. The live board shows what is moving right now, scored against real money.
Open this story live → See today's live boardEarlier on Moderna
- Moderna's Melanoma Vaccine Trial Ignites Chatter August 19, 2026
More Stocks stories
- Schneider Electric's $22.6B Deal Sends PTC Soaring October 6, 2026
- Stripe's $7B OpenRouter Deal Gets Picked Apart October 6, 2026
- Amazon Chatter Is Loud, the Stock Isn't Moving October 6, 2026
- Amazon's news cycle is loud, the stock isn't moving October 6, 2026
- CapsoVision Ticker Collision Hides a Real 6.7% Pop October 5, 2026
- Cerebras Rips Higher on OpenAI Partnership Chatter October 5, 2026
Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything — you decide.